Santen Pharmaceutical-Un ADRSNPHY
13F holders, Q1 2025 (March 31)2holders −1
0new positions
1sold out
$9.47avg. 13F price*
At the end of Q1 2025, 2 institutions reported holding Santen Pharmaceutical-Un ADR (SNPHY) in their 13F filings, down 1 from Q4 2024. 0 opened new positions and 1 sold out. The largest holders were Copeland Capital Management, LLC ($2K) and Rhumbline Advisers ($284).
- Company
- Santen Pharmaceutical-Un ADR
- CUSIP
- 80287P100
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $268 |
All 13F filers, Q4 2024 → Q1 2025: 26 shares sold, net −26 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Copeland Capital Management, LLC | 0.00% | No change | 230 | $2K |
| Rhumbline Advisers | 0.00% | No change | 30 | $284 |
"% of holder's portfolio" is SNPHY's weight in each manager's 13F, not the share of Santen Pharmaceutical-Un ADR the manager owns.